ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 272

Interim Safety Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC10004) in Subjects with Erosive Hand Osteoarthritis

Juergen Rech1, Wolfgang Ochs2, Wolfgang Spieler3, Herbert Kellner4, Ulf Müller-Ladner5, Mathias Grunke6, Matthias Schneider7 and Georg Schett8, 1Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 2Rheumatologist in private practice, Bayreuth, Germany, 3Rheumatology Specialty Practice, Zerbst, Germany, 4Centre for Inflammatory Joint Diseases, Munich, Germany, 5Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 6Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 7Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Apremilast is a small molecule,specific phospodiesterase4 inhibitor under investigation for a number of inflammatory conditions, including psoriasis and psoriatic arthritis. We report results of an interim safety analysis of a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in 18 patients with erosive hand osteoarthritis (EHOA).

Methods: Subjects with a diagnosis of EHOA, fulfilling the classification criteria of the American College of Rheumatology with a disease duration of ≥6 months, were randomized to oral apremilast 20 mg BID or matching placebo. All subjects with at least the baseline visit reported were included in the analysis. Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.

Results: A total of 76 AEs were reported since the study started in 2010 (FPFV 29-Nov-2010, data lock for interim analysis 30-May-2012). Most AEs were mild to moderate in severity (93.5%); only 5 (6.6%) were grade 3 (severe). No grade 4 or 5 AEs were reported. The most commonly reported AEs were related to “Pain ” 38% (Pain-Head/headache in 6/11 patients (55%) and Pain-Joint in 3/11 patients (27%) or “Gastrointestinal” (18%), with the most frequent AEs being headache (16%), fatigue (8%), diarrhea (7%), and joint pain (7%). Thirty-five AEs (46%) were considered possibly treatment related. Of these, 97% were mild to moderate and only 1 (3%) was grade 3 (hypotension). The most frequent treatment-related AEs were headache (9/35 [26%]), fatigue (3/35 [9%]), and diarrhea (3/35 [9%]). No serious AEs or deaths were reported during the study.

Conclusion: Given the lack of treatment options for patients with EHOA, there is an unmet need for an effective treatment to reduce the burden of this disease. Considering the pathophysiology of EHOA, mechanism of action of phosphodiesterase 4 inhibitors, and the reported AEs in earlier trials, we conclude that apremilast may also be well tolerated in patients with EHOA. Apremilast, if proven to be efficacious in ongoing investigations, will be an interesting treatment option for patients with EHOA.



Disclosure:

J. Rech,
None;

W. Ochs,
None;

W. Spieler,
None;

H. Kellner,
None;

U. Müller-Ladner,

Actelion Pharmaceuticals Ltd,

5;

M. Grunke,
None;

M. Schneider,
None;

G. Schett,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interim-safety-analysis-of-a-phase-2-multicenter-randomized-double-blind-placebo-controlled-parallel-group-efficacy-study-of-apremilast-cc10004-in-subjects-with-erosive-hand-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology